Chennai, India, February
17, 2026 : PAT rose 578% compared to last year as Kabra Drugs Limited
(BSE: 524322), a fast‑emerging microcap company, announced its unaudited financial results for
the quarter ended December 31, 2025, on February 13, 2026, alongside a series
of strategic initiatives approved earlier on January 1, 2026. Together, these
milestones underscore the Company’s turnaround momentum, its
diversification into high‑growth industries, and the strong investor rally that has driven its
stock up nearly 200% over the past year.
For the December quarter,
Kabra Drugs reported revenue of ₹30.42 crore, marking a sharp 53.9%
increase over the September 2025 quarter revenue of ₹19.76 crore, and a complete
turnaround from nil revenue in December 2024.
Profit After Tax stood at
₹2.56 crore, representing a 39.7% sequential rise QoQ compared to ₹1.84 crore in September 2025, and a dramatic 578% YoY
swing from a loss of ₹53.69 lakhs in the same period last year.
Don’t forget, the Company
is also planning to enter into multiple new business streams, including
manufacturing of medical equipment, as per their announcements given in the
BSE exchange earlier.
Alongside this, Kabra Drugs
signed an agreement with MR Franchise to appoint 200 channel partners
nationwide, strengthening its distribution reach and market presence. The
Board has also proposed a name change to better reflect its evolving business
direction, subject to shareholder and regulatory approvals.
The financial results have
been reviewed by the Audit Committee and subjected to a limited review by
statutory auditors. Strategic initiatives remain subject to shareholder and
regulatory approvals. All disclosures are made in compliance with SEBI (LODR)
Regulations, 2015.
Disclaimer :
This communication is for informational purposes only and is based
on publicly available disclosures made by the Company. It does not constitute investment
advice, a recommendation, or a solicitation to buy or sell any securities.
Certain statements may be forward-looking and are subject to risks
and uncertainties that may cause actual outcomes to differ materially. Past
performance is not indicative of future results or growth.
Readers
should exercise independent judgment and consult qualified advisors before
making any investment decisions. No liability is accepted for any loss arising
from reliance on this information by any of the parties.